Richard Rodgers
Directeur/Membre du Conseil chez ARDELYX, INC.
Fortune : 2 M $ au 30/04/2024
Profil
Mr. Richard J.
Rodgers is an Independent Director at Novavax, Inc., an Independent Director at Ocuphire Pharma, Inc. and an Independent Director at Ardelyx, Inc. He is on the Board of Directors at Novavax, Inc., Ocuphire Pharma, Inc. and Ardelyx, Inc. Mr. Rodgers was previously employed as an Independent Director by Sagimet Biosciences, Inc., an Independent Director by Rexahn Pharmaceuticals, Inc., a CFO, Secretary, Treasurer & Executive VP by Tesaro, Inc., a Chief Financial Officer & Senior Vice President by Abraxis BioScience, Inc., a Chief Accounting Officer, Senior VP & Controller by MGI PHARMA, Inc., a Controller by MedSource Technologies Holdings LLC, a Principal by ADC Telecommunications, Inc., and a Principal by Arthur Andersen LLP.
He received his undergraduate degree from St. Cloud State University and an MBA from The Curtis L.
Carlson School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARDELYX, INC.
0,10% | 15/04/2024 | 238 320 ( 0,10% ) | 2 M $ | 30/04/2024 |
OCUPHIRE PHARMA, INC.
0,66% | 15/04/2024 | 163 008 ( 0,66% ) | 250 217 $ | 30/04/2024 |
NOVAVAX, INC.
0,01% | 22/04/2024 | 10 470 ( 0,01% ) | 45 335 $ | 30/04/2024 |
| 18/07/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Richard Rodgers
| Sociétés | Poste | Début |
|---|---|---|
| ARDELYX, INC. | Directeur/Membre du Conseil | 01/03/2014 |
| OCUPHIRE PHARMA, INC. | Directeur/Membre du Conseil | 01/11/2020 |
| NOVAVAX, INC. | Directeur/Membre du Conseil | 29/10/2022 |
Anciens postes connus de Richard Rodgers
| Sociétés | Poste | Fin |
|---|---|---|
| SAGIMET BIOSCIENCES INC. | Directeur/Membre du Conseil | 05/06/2024 |
| REXAHN PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/11/2020 |
| TESARO INC | Fondateur | 31/08/2013 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Directeur Financier/CFO | 03/02/2010 |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Comptroller/Controller/Auditor | 01/01/2008 |
Formation de Richard Rodgers
| St. Cloud State University | Undergraduate Degree |
| The Curtis L. Carlson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ARDELYX, INC. | Health Technology |
| SAGIMET BIOSCIENCES INC. | Health Technology |
| OCUPHIRE PHARMA, INC. | Health Technology |
| NOVAVAX, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Health Technology |
MedSource Technologies Holdings LLC
 MedSource Technologies Holdings LLC Medical SpecialtiesHealth Technology MedSource Technologies Holdings LLC provides engineering, manufacturing, and supply chain management services for the medical device industry. The company was founded by Andrew D. Lipman, Richard J. Effress, and William John Kidd on April 1998 and is headquartered in Wilmington, MA. | Health Technology |
Arthur Andersen LLP
 Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Commercial Services |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
ADC Telecommunications, Inc.
 ADC Telecommunications, Inc. Telecommunications EquipmentElectronic Technology ADC is a global leader in providing network infrastructure products and services that enable the profitable delivery of high-speed Internet, video, data, and voice services to residential, business and mobile subscribers worldwide. Their innovative, high-performance fiber connectivity and wireless coverage and capacity solutions support a broad range of network applications that help their customers provide new and advanced services to meet their own customers' unrelenting demand for bandwidth. Founded 75 years ago, ADC continues to build on a strong heritage of providing solutions and services that support its customers' migration to next-generation networks in many countries across the globe. As the leading service providers and enterprises worldwide invest in infrastructure that delivers broadband services to business, residential and mobile subscribers, ADC's breadth of solutions and experience, together with its strong financial position, make the company a reliable partner in addressing today's network realities and preparing for tomorrow's communications demands. | Electronic Technology |
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
